Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients

Hongyi Chen, Zhicheng Zhang, Li Wang, Zhihua Huang, Fanghua Gong, Xiaodong Li, Yahong Chen, Jinzi J. Wu
doi: https://doi.org/10.1101/2020.03.22.20034041
Hongyi Chen
1The first department of infectious disease, the nineth hospital of Nanchang, Nanchang, Jiangxi province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jinzi.wu@ascletis.com chenhongyi@163.com
Zhicheng Zhang
2The intensive care unit, the nineth hospital of Nanchang, Nanchang, Jiangxi province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Wang
1The first department of infectious disease, the nineth hospital of Nanchang, Nanchang, Jiangxi province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhihua Huang
3The radiology department, the nineth hospital of Nanchang, Nanchang, Jiangxi province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanghua Gong
4The second department of infectious disease, the nineth hospital of Nanchang, Nanchang, Jiangxi province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaodong Li
5Ascletis Bioscience Co., Ltd., Hangzhou, Zhejiang province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yahong Chen
5Ascletis Bioscience Co., Ltd., Hangzhou, Zhejiang province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinzi J. Wu
5Ascletis Bioscience Co., Ltd., Hangzhou, Zhejiang province, China
6Ascletis pharmaceuticals Co., Ltd., Shaoxing, Zhejiang province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jinzi.wu@ascletis.com chenhongyi@163.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the first clinical study using hepatitis C virus (HCV) protease inhibitor, danoprevir, to treat COVID-19 patients. Danoprevir (Ganovo®) is a potent HCV protease (NS3/4A) inhibitor (IC50 = 0.29 nM), which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. Ritonavir is a CYP3A4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus (HIV) protease inhibitor at high doses. The chymotrypsin-like protease of SARS-CoV-2 shares structure similarity with HCV and HIV proteases. In the current clinical study (NCT04291729) conducted at the Nineth Hospital of Nanchang, we evaluated therapeutic effects of danoprevir, boosted by ritonavir, on treatment naïve and experienced COVID-19 patients. The data from this small-sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients. After 4 to 12-day treatment of danoprevir boosted by ritonavir, all eleven patients enrolled, two naïve and nine experienced, were discharged from the hospital as they met all four conditions as follows: (1) normal body temperature for at least 3 days; (2) significantly improved respiratory symptoms; (3) lung imaging shows obvious absorption and recovery of acute exudative lesion; and (4) two consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid (respiratory track sampling with interval at least one day). Our findings suggest that repurposing danoprevir for COVID-19 is a promising therapeutic option.

Competing Interest Statement

Jinzi J Wu, PhD, one of the corresponding authors, is Chief Executive Officer of Ascletis Pharmaceuticals Co., Ltd. and Ascletis Bioscience Co., Ltd. (together “Ascletis”) which provided danoprevir and ritonavir and technical support to this study. Xiaodong Li and Yahong Chen are employees of Ascletis Bioscience Co. Ltd. Ascletis markets and sells danoprevir in China. The work described was original research that has not been published previously. All the authors listed have approved the manuscript that is enclosed. No other interest needs to be declared.

Clinical Trial

NCT04291729

Funding Statement

This study is partially funded by Science and Technology Bureau of Nanchang City.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The work described was original research that has not been published previously.

  • Abbreviations

    COVID-19
    coronavirus disease 2019
    SARS-COV2
    severe acute respiratory syndrome coronavirus-2
    MERS
    middle east respiratory syndrome
    GGO
    ground glass opacity
    RT-PCR
    reverse real-time PCR
    HIV
    human immunodeficiency virus
    HCV
    hepatitis C virus
    3CL pro
    chymotrypsin-like protease
    GT
    genotype
    WHO
    World Health Organization
    SVR
    sustained virologic response
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted March 24, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients
    Hongyi Chen, Zhicheng Zhang, Li Wang, Zhihua Huang, Fanghua Gong, Xiaodong Li, Yahong Chen, Jinzi J. Wu
    medRxiv 2020.03.22.20034041; doi: https://doi.org/10.1101/2020.03.22.20034041
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients
    Hongyi Chen, Zhicheng Zhang, Li Wang, Zhihua Huang, Fanghua Gong, Xiaodong Li, Yahong Chen, Jinzi J. Wu
    medRxiv 2020.03.22.20034041; doi: https://doi.org/10.1101/2020.03.22.20034041

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (240)
    • Allergy and Immunology (521)
    • Anesthesia (125)
    • Cardiovascular Medicine (1420)
    • Dentistry and Oral Medicine (217)
    • Dermatology (158)
    • Emergency Medicine (291)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
    • Epidemiology (10297)
    • Forensic Medicine (6)
    • Gastroenterology (527)
    • Genetic and Genomic Medicine (2629)
    • Geriatric Medicine (254)
    • Health Economics (497)
    • Health Informatics (1733)
    • Health Policy (789)
    • Health Systems and Quality Improvement (673)
    • Hematology (266)
    • HIV/AIDS (565)
    • Infectious Diseases (except HIV/AIDS) (12093)
    • Intensive Care and Critical Care Medicine (649)
    • Medical Education (273)
    • Medical Ethics (83)
    • Nephrology (289)
    • Neurology (2461)
    • Nursing (145)
    • Nutrition (377)
    • Obstetrics and Gynecology (493)
    • Occupational and Environmental Health (568)
    • Oncology (1324)
    • Ophthalmology (401)
    • Orthopedics (146)
    • Otolaryngology (237)
    • Pain Medicine (168)
    • Palliative Medicine (51)
    • Pathology (343)
    • Pediatrics (780)
    • Pharmacology and Therapeutics (330)
    • Primary Care Research (296)
    • Psychiatry and Clinical Psychology (2397)
    • Public and Global Health (5007)
    • Radiology and Imaging (893)
    • Rehabilitation Medicine and Physical Therapy (528)
    • Respiratory Medicine (681)
    • Rheumatology (309)
    • Sexual and Reproductive Health (256)
    • Sports Medicine (245)
    • Surgery (298)
    • Toxicology (45)
    • Transplantation (140)
    • Urology (108)